Published: 22 August 2019
Author(s): Ana Clara Ladeira Cruz, Marina Pereira Colella, Erich Vinícius De Paula, Joyce Annichinno-Bizzachi, Fernanda Andrade Orsi
Issue: August 2019
Section: Letter to the Editor

Antiphospholipid antibodies (aPL) are frequently detected in immune thrombocytopenia (ITP) and whether they play a role in ITP prognosis is controversial. Previous studies have shown that aPL positivity may not be associated with either platelet counts or response to treatment [1–4]; however, heterogeneity in the classification of ITP outcomes and high variability of aPL assays performed across studies may affect results consistency.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.